Fundraising FoxNovartis Venture Fund — 2012 Investments
2 investments dated 2012 · listed companies and verified rows first · show all
F2Gf2g.comSep 2012 · $30M
F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAdvent Life SciencesAisling CapitalAMR Action FundAstellas Venture Management LLCBrace PharmaSofinnova Partners+4 more
Tepha, Inc.tepha.comMar 2012
HealthtechLexington, US
Simon Williams(Executive Officer, Director)John Hartnett(Executive Officer)
BoardRichard B. Emmitt(Director)inEdward M. Giles(Director)Anthony J. Sinskey(Director)
Co-investorsThe Vertical Group
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.